Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bimatoprost 0.01% in the Clinical Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary open-angle glaucoma or ocular hypertension~* Determined by the treating physician to require treatment with bimatoprost 0.01%.~Exclusion Criteria:~* Previous use of Lumigan® 0.01%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pts with POAG or OH (Previously Treatment Naive) (Type: None): Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
- Pts with POAG or OH (Switched Monotherapy) (Type: None): Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

Based on this trial design, predict the completion outcome and termination type (if applicable).